These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30403937)

  • 1. A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.
    King CL; Suamani J; Sanuku N; Cheng YC; Satofan S; Mancuso B; Goss CW; Robinson LJ; Siba PM; Weil GJ; Kazura JW
    N Engl J Med; 2018 Nov; 379(19):1801-1810. PubMed ID: 30403937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
    Thomsen EK; Sanuku N; Baea M; Satofan S; Maki E; Lombore B; Schmidt MS; Siba PM; Weil GJ; Kazura JW; Fleckenstein LL; King CL
    Clin Infect Dis; 2016 Feb; 62(3):334-341. PubMed ID: 26486704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
    Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
    PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
    Edi C; Bjerum CM; Ouattara AF; Chhonker YS; Penali LK; Méité A; Koudou BG; Weil GJ; King CL; Murry DJ
    PLoS Negl Trop Dis; 2019 May; 13(5):e0007325. PubMed ID: 31107869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
    Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
    Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
    Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
    Supali T; Djuardi Y; Christian M; Iskandar E; Alfian R; Maylasari R; Destani Y; Lomiga A; Minggu D; Lew D; Bogus J; Weil GJ; Fischer PU
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009294. PubMed ID: 33780481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.
    Dubray CL; Sircar AD; Beau de Rochars VM; Bogus J; Direny AN; Ernest JR; Fayette CR; Goss CW; Hast M; O'Brian K; Pavilus GE; Sabin DF; Wiegand RE; Weil GJ; Lemoine JF
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008298. PubMed ID: 32511226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d'Ivoire: An Open-label Randomized Controlled Trial.
    Bjerum CM; Ouattara AF; Aboulaye M; Kouadio O; Marius VK; Andersen BJ; Weil GJ; Koudou BG; King CL
    Clin Infect Dis; 2020 Oct; 71(7):e68-e75. PubMed ID: 31641754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass treatment to eliminate filariasis in Papua New Guinea.
    Bockarie MJ; Tisch DJ; Kastens W; Alexander ND; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
    N Engl J Med; 2002 Dec; 347(23):1841-8. PubMed ID: 12466508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Dose Triple-Drug Therapy for
    King CL; Weil GJ; Kazura JW
    N Engl J Med; 2020 May; 382(20):1956-1957. PubMed ID: 32402169
    [No Abstract]   [Full Text] [Related]  

  • 12. Endpoints for lymphatic filariasis programs.
    Grady CA; de Rochars MB; Direny AN; Orelus JN; Wendt J; Radday J; Mathieu E; Roberts JM; Streit TG; Addiss DG; Lammie PJ
    Emerg Infect Dis; 2007 Apr; 13(4):608-10. PubMed ID: 17553278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters.
    Wamae CN; Njenga SM; Ngugi BM; Mbui J; Njaanake HK
    Acta Trop; 2011 Sep; 120 Suppl 1():S33-8. PubMed ID: 20933491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.
    Bockarie MJ; Alexander ND; Hyun P; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
    Lancet; 1998 Jan; 351(9097):162-8. PubMed ID: 9449870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.
    de Souza DK; Ahorlu CS; Adu-Amankwah S; Otchere J; Mensah SK; Larbi IA; Mensah GE; Biritwum NK; Boakye DA
    Trials; 2017 Oct; 18(1):448. PubMed ID: 28969715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ivermectin for control of microfilaremia recurring after treatment with diethylcarbamazine. I. Clinical and parasitologic observations.
    Zheng HJ; Piessens WF; Tao ZH; Cheng WF; Wang SH; Cheng SH; Ye YM; Luo LF; Chen XR; Gan GB
    Am J Trop Med Hyg; 1991 Aug; 45(2):168-74. PubMed ID: 1877711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis.
    Wkly Epidemiol Rec; 2003 Sep; 78(36):315-7. PubMed ID: 14518107
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature.
    Budge PJ; Herbert C; Andersen BJ; Weil GJ
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006454. PubMed ID: 29768412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
    Irvine MA; Stolk WA; Smith ME; Subramanian S; Singh BK; Weil GJ; Michael E; Hollingsworth TD
    Lancet Infect Dis; 2017 Apr; 17(4):451-458. PubMed ID: 28012943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
    de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
    Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.